Anacetrapib (BioDeep_00000658000)
代谢物信息卡片
Anacetrapib
化学式: C30H25F10NO3 (637.1674659999999)
中文名称: 安塞曲匹
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
InChI: InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1
描述信息
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
D000890 - Anti-Infective Agents > D023303 - Oxazolidinones
D009676 - Noxae > D000963 - Antimetabolites
C471 - Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D08855
- PubChem: 11556427
- DrugBank: DB06630
- ChEMBL: CHEMBL1800807
- CAS: 875446-37-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mathieu R Brodeur, David Rhainds, Daniel Charpentier, Marie Boulé, Téodora Mihalache-Avram, Mélanie Mecteau, Geneviève Brand, Valérie Pedneault-Gagnon, Annik Fortier, Eric J Niesor, Eric Rhéaume, Cyrille Maugeais, Jean-Claude Tardif. Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.
Journal of lipid research.
2023 01; 64(1):100316. doi:
10.1016/j.jlr.2022.100316. [PMID: 36410424] - E Sammons, J C Hopewell, F Chen, W Stevens, K Wallendszus, E Valdes-Marquez, R Dayanandan, C Knott, K Murphy, E Wincott, A Baxter, R Goodenough, M Lay, M Hill, S Macdonnell, G Fabbri, D Lucci, M Fajardo-Moser, S Brenner, D Hao, H Zhang, J Liu, B Wuhan, S Mosegaard, W Herrington, C Wanner, C Angermann, G Ertl, A Maggioni, P Barter, B Mihaylova, Y Mitchel, R Blaustein, S Goto, J Tobert, P DeLucca, Y Chen, Z Chen, A Gray, R Haynes, J Armitage, C Baigent, S Wiviott, C Cannon, E Braunwald, R Collins, L Bowman, M Landray. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
European heart journal.
2022 04; 43(14):1416-1424. doi:
10.1093/eurheartj/ehab863. [PMID: 34910136] - Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, Christopher J O'Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Nature communications.
2021 09; 12(1):5640. doi:
10.1038/s41467-021-25703-3. [PMID: 34561430] - Petr Vachal, Joseph L Duffy, Louis-Charles Campeau, Rupesh P Amin, Kaushik Mitra, Beth Ann Murphy, Pengcheng P Shao, Peter J Sinclair, Feng Ye, Revathi Katipally, Zhijian Lu, Debra Ondeyka, Yi-Heng Chen, Kake Zhao, Wanying Sun, Sriram Tyagarajan, Jianming Bao, Sheng-Ping Wang, Josee Cote, Concetta Lipardi, Daniel Metzger, Dennis Leung, Georgy Hartmann, Gordon K Wollenberg, Jian Liu, Lushi Tan, Yingju Xu, Qinghao Chen, Guiquan Liu, Robert O Blaustein, Douglas G Johns. Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Journal of medicinal chemistry.
2021 09; 64(18):13215-13258. doi:
10.1021/acs.jmedchem.1c00959. [PMID: 34375108] - Hanjing Chen, Weili Chen, Hui Li, Hongrong Xu, Fei Yuan, Lei Sheng, Chao Liu, Pingping Lin, Mengjie Yang, Xuening Li, Yang Liu, Brittany Marie Walker, Ferdous Gheyas, Marian Iwamoto, S Aubrey Stoch, Rajesh Krishna. Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects.
Advances in therapy.
2021 07; 38(7):3973-3985. doi:
10.1007/s12325-021-01794-8. [PMID: 34101144] - Mark Trinder, Yanan Wang, Christian M Madsen, Tatjana Ponomarev, Lubos Bohunek, Brendan A Daisely, HyeJin Julia Kong, Lisanne L Blauw, Børge G Nordestgaard, Anne Tybjærg-Hansen, Mark M Wurfel, James A Russell, Keith R Walley, Patrick C N Rensen, John H Boyd, Liam R Brunham. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
Circulation.
2021 03; 143(9):921-934. doi:
10.1161/circulationaha.120.048568. [PMID: 33228395] - Mark P Metzinger, Suzanne Saldanha, Jaskeerat Gulati, Kershaw V Patel, Ayea El-Ghazali, Sneha Deodhar, Parag H Joshi, Colby Ayers, Anand Rohatgi. Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.
Journal of the American Heart Association.
2020 12; 9(24):e018136. doi:
10.1161/jaha.120.018136. [PMID: 33263263] - Chao Chen, Renhua Sun, Yan Sun, Xuan Chen, Fei Li, Xiaoan Wen, Haoliang Yuan, Dongyin Chen. Synthesis, biological evaluation and SAR studies of ursolic acid 3β-ester derivatives as novel CETP inhibitors.
Bioorganic & medicinal chemistry letters.
2020 01; 30(2):126824. doi:
10.1016/j.bmcl.2019.126824. [PMID: 31780304] - Douglas G Johns, Sheng-Ping Wang, Raymond Rosa, James Hubert, Suoyu Xu, Ying Chen, Thomas Bateman, Robert O Blaustein. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
Pharmacology research & perspectives.
2019 12; 7(6):e00543. doi:
10.1002/prp2.543. [PMID: 31832204] - Ben J Wu, Yue Li, Kwok-Leung Ong, Yidan Sun, Douglas Johns, Philip J Barter, Kerry-Anne Rye. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.
Scientific reports.
2019 11; 9(1):16183. doi:
10.1038/s41598-019-52510-0. [PMID: 31700015] - Sneha M Dixit, Mohd Ahsan, Sanjib Senapati. Steering the Lipid Transfer To Unravel the Mechanism of Cholesteryl Ester Transfer Protein Inhibition.
Biochemistry.
2019 09; 58(36):3789-3801. doi:
10.1021/acs.biochem.9b00301. [PMID: 31418269] - Douglas G Johns, Lauretta LeVoci, Mihajlo Krsmanovic, Min Lu, Georgy Hartmann, Suoyu Xu, Sheng-Ping Wang, Ying Chen, Thomas Bateman, Robert O Blaustein. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes.
Drug metabolism and disposition: the biological fate of chemicals.
2019 03; 47(3):227-233. doi:
10.1124/dmd.118.084525. [PMID: 30567880] - Lin Zhu, Thao Luu, Christopher H Emfinger, Bryan A Parks, Jeanne Shi, Elijah Trefts, Fenghua Zeng, Zsuzsanna Kuklenyik, Raymond C Harris, David H Wasserman, Sergio Fazio, John M Stafford. CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet.
Diabetes.
2018 12; 67(12):2494-2506. doi:
10.2337/db18-0474. [PMID: 30213825] - Rajesh Krishna, Ferdous Gheyas, Christy Corr, Josee Cote, Yang Liu, John Wagner, David E Gutstein. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
Journal of clinical pharmacology.
2018 12; 58(12):1578-1585. doi:
10.1002/jcph.1287. [PMID: 30029292] - Philip J Barter, Blake J Cochran, Kerry-Anne Rye. CETP inhibition, statins and diabetes.
Atherosclerosis.
2018 11; 278(?):143-146. doi:
10.1016/j.atherosclerosis.2018.09.033. [PMID: 30278356] - Zhiwei Yang, Yang Cao, Dongxiao Hao, Xiaohui Yuan, Lei Zhang, Shengli Zhang. Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.
Journal of biomolecular structure & dynamics.
2018 Aug; 36(10):2567-2580. doi:
10.1080/07391102.2017.1363661. [PMID: 28777919] - Yusuke Masuda, Shinji Yamaguchi, Chikako Suzuki, Takahide Aburatani, Yuki Nagano, Ryuki Miyauchi, Eiko Suzuki, Naotoshi Yamamura, Kentaro Nagatomo, Hidetoshi Ishihara, Kazuaki Okuno, Futoshi Nara, Gabriele Matschiner, Ryuji Hashimoto, Tohru Takahashi, Tomohiro Nishizawa. Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein.
The Journal of pharmacology and experimental therapeutics.
2018 05; 365(2):368-378. doi:
10.1124/jpet.117.246652. [PMID: 29463608] - Sheila A Doggrell. Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?.
Expert opinion on pharmacotherapy.
2018 Apr; 19(6):611-615. doi:
10.1080/14656566.2018.1448061. [PMID: 29498299] - Rajesh Krishna, Ferdous Gheyas, Yang Liu, Josee Cote, Omar Laterza, Jon L Ruckle, John A Wagner, Andrew E Denker. Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
Journal of clinical pharmacology.
2018 02; 58(2):254-262. doi:
10.1002/jcph.1004. [PMID: 28884824] - Alan R Tall, Daniel J Rader. Trials and Tribulations of CETP Inhibitors.
Circulation research.
2018 01; 122(1):106-112. doi:
10.1161/circresaha.117.311978. [PMID: 29018035] - R Krishna, F Gheyas, Y Liu, D R Hagen, B Walker, A Chawla, J Cote, R O Blaustein, D E Gutstein. Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.
Clinical pharmacology and therapeutics.
2017 Nov; 102(5):832-840. doi:
10.1002/cpt.700. [PMID: 28380664] - Luis Masana. Results of the REVEAL study. Why Should we not welcome a new lipid lowering agent?.
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.
2017 Nov; 29(6):278-279. doi:
10.1016/j.arteri.2017.10.002. [PMID: 29173491] - Ken Yamada, Margaret Brousseau, Wataru Honma, Akiko Iimura, Hidetomo Imase, Yuki Iwaki, Toshio Kawanami, Daniel LaSala, Guiqing Liang, Hironobu Mitani, Kazuhiko Nonomura, Osamu Ohmori, Meihui Pan, Dean F Rigel, Ichiro Umemura, Kayo Yasoshima, Guoming Zhu, Muneto Mogi. Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.
Journal of medicinal chemistry.
2017 10; 60(20):8466-8481. doi:
10.1021/acs.jmedchem.7b00900. [PMID: 29035537] - Dongyin Chen, Xin Huang, Hongwen Zhou, Hanqiong Luo, Pengfei Wang, Yongzhi Chang, Xinyi He, Suiying Ni, Qingqing Shen, Guoshen Cao, Hongbin Sun, Xiaoan Wen, Jun Liu. Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
European journal of medicinal chemistry.
2017 Oct; 139(?):201-213. doi:
10.1016/j.ejmech.2017.08.012. [PMID: 28802120] - Theodosios D Filippatos, Anastazia Kei, Moses S Elisaf. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?.
Diseases (Basel, Switzerland).
2017 Sep; 5(4):. doi:
10.3390/diseases5040021. [PMID: 28961179] - Tiffany Thomas, Haihong Zhou, Wahida Karmally, Rajasekhar Ramakrishnan, Stephen Holleran, Yang Liu, Patricia Jumes, John A Wagner, Brian Hubbard, Stephen F Previs, Thomas Roddy, Amy O Johnson-Levonas, David E Gutstein, Santica M Marcovina, Daniel J Rader, Henry N Ginsberg, John S Millar, Gissette Reyes-Soffer. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
Arteriosclerosis, thrombosis, and vascular biology.
2017 09; 37(9):1770-1775. doi:
10.1161/atvbaha.117.309549. [PMID: 28729361] - Christie M Ballantyne, Sukrut Shah, Aditi Sapre, Tanya B Ashraf, Sandra C Tobias, Tayfun Sahin, Ping Ye, Yugang Dong, Wayne Huey-Heng Sheu, Duk-Hyun Kang, Paulo Roberto Ferreira Rossi, Yulia Moiseeva, Ignacio Rodriguez Briones, Amy O Johnson-Levonas, Yale B Mitchel. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
The American journal of cardiology.
2017 Aug; 120(4):569-576. doi:
10.1016/j.amjcard.2017.03.255. [PMID: 28624096] - Mathieu R Brodeur, David Rhainds, Daniel Charpentier, Teodora Mihalache-Avram, Mélanie Mecteau, Geneviève Brand, Evelyne Chaput, Anne Perez, Eric J Niesor, Eric Rhéaume, Cyrille Maugeais, Jean-Claude Tardif. Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys.
Journal of lipid research.
2017 07; 58(7):1282-1291. doi:
10.1194/jlr.m068940. [PMID: 28515138] - John S Millar, Michael E Lassman, Tiffany Thomas, Rajasekhar Ramakrishnan, Patricia Jumes, Richard L Dunbar, Emil M deGoma, Amanda L Baer, Wahida Karmally, Daniel S Donovan, Hashmi Rafeek, John A Wagner, Stephen Holleran, Joseph Obunike, Yang Liu, Soumia Aoujil, Taylor Standiford, David E Gutstein, Henry N Ginsberg, Daniel J Rader, Gissette Reyes-Soffer. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
Journal of lipid research.
2017 06; 58(6):1214-1220. doi:
10.1194/jlr.m074880. [PMID: 28314859] - Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki, Hidenori Arai, Yuko Maeda, Mariko Nakagomi, Masayoshi Shirakawa, Yuichiro Watanabe, Taro Kakikawa, Hirotaka Numaguchi, Amy O Johnson-Levonas, Robert O Blaustein. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
Atherosclerosis.
2017 06; 261(?):69-77. doi:
10.1016/j.atherosclerosis.2017.03.009. [PMID: 28478132] - Amanda L Brown, J Mark Brown. Anacetrapib-driven triglyceride lowering explained: the fortuitous role of CETP in the intravascular catabolism of triglyceride-rich lipoproteins.
Journal of lipid research.
2017 06; 58(6):1031-1032. doi:
10.1194/jlr.c077131. [PMID: 28432183] - Spencer Phillips Hey, Jessica M Franklin, Jerry Avorn, Aaron S Kesselheim. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Circulation. Cardiovascular quality and outcomes.
2017 Jun; 10(6):. doi:
10.1161/circoutcomes.116.003121. [PMID: 28611186] - L Bowman, F Chen, E Sammons, J C Hopewell, K Wallendszus, W Stevens, E Valdes- Marquez, S Wiviott, C P Cannon, E Braunwald, R Collins, M J Landray. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
American heart journal.
2017 05; 187(?):182-190. doi:
10.1016/j.ahj.2017.02.021. [PMID: 28454801] - Sang-Bum Kim, Ki Taek Kim, Jeongmin Joo, Kyung-Ah Seo, Hayoung Hwang, Soong-Hyun Kim, Minsoo Song, Sungwoo Lee, Alexander Jahn, Hyun-Jong Cho, Dae-Duk Kim, In-Soo Yoon. Assessment of pharmacokinetics, bioavailability and protein binding of anacetrapib in rats by a simple high-performance liquid chromatography-tandem mass spectrometry method.
Biomedical chromatography : BMC.
2017 Feb; 31(2):. doi:
10.1002/bmc.3791. [PMID: 27432781] - Claudio Borghi, Arrigo F G Cicero. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.
Expert opinion on drug metabolism & toxicology.
2017 Feb; 13(2):205-209. doi:
10.1080/17425255.2017.1262347. [PMID: 27852117] - Christie M Ballantyne, Sukrut Shah, Uma Kher, John A Hunter, Geraldine G Gill, Michael D Cressman, Tanya B Ashraf, Amy O Johnson-Levonas, Yale B Mitchel. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
The American journal of cardiology.
2017 Feb; 119(3):388-396. doi:
10.1016/j.amjcard.2016.10.032. [PMID: 27956003] - Ziyun Wang, Manabu Niimi, Qianzhi Ding, Zhenming Liu, Ling Wang, Jifeng Zhang, Jun Xu, Jianglin Fan. Comparative studies of three cholesteryl ester transfer proteins and their interactions with known inhibitors.
PloS one.
2017; 12(8):e0180772. doi:
10.1371/journal.pone.0180772. [PMID: 28767652] - Venkat R Chirasani, Revathi Sankar, Sanjib Senapati. Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors.
The journal of physical chemistry. B.
2016 08; 120(33):8254-63. doi:
10.1021/acs.jpcb.6b01928. [PMID: 27111423] - T D Filippatos, E Klouras, F Barkas, M Elisaf. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Expert review of cardiovascular therapy.
2016 Aug; 14(8):953-62. doi:
10.1080/14779072.2016.1189327. [PMID: 27171534] - Eder C R Quintão. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?.
European journal of clinical investigation.
2016 Jun; 46(6):581-9. doi:
10.1111/eci.12626. [PMID: 26992444] - Hidenori Arai, Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki, Yuko Maeda, Mariko Nakagomi, Masayoshi Shirakawa, Taro Kakikawa, Hirotaka Numaguchi, Amy O Johnson-Levonas, Sanskruti Vaidya, Robert O Blaustein. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
Atherosclerosis.
2016 06; 249(?):215-23. doi:
10.1016/j.atherosclerosis.2016.03.017. [PMID: 27131642] - Gissette Reyes-Soffer, John S Millar, Colleen Ngai, Patricia Jumes, Ellie Coromilas, Bela Asztalos, Amy O Johnson-Levonas, John A Wagner, Daniel S Donovan, Wahida Karmally, Rajasekhar Ramakrishnan, Stephen Holleran, Tiffany Thomas, Richard L Dunbar, Emil M deGoma, Hashmi Rafeek, Amanda L Baer, Yang Liu, Michael E Lassman, David E Gutstein, Daniel J Rader, Henry N Ginsberg. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Arteriosclerosis, thrombosis, and vascular biology.
2016 05; 36(5):994-1002. doi:
10.1161/atvbaha.115.306680. [PMID: 26966279] - David G McLaren, Stephen F Previs, Robert D Phair, Steven J Stout, Dan Xie, Ying Chen, Gino M Salituro, Suoyu S Xu, Jose M Castro-Perez, Gregory J Opiteck, Karen O Akinsanya, Michele A Cleary, Hayes M Dansky, Douglas G Johns, Thomas P Roddy. Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux.
Journal of lipid research.
2016 Mar; 57(3):398-409. doi:
10.1194/jlr.m063842. [PMID: 26658238] - C M Chavez-Eng, R W Lutz, H Li, D Goykhman, K P Bateman, E Woolf. Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Feb; 1011(?):204-14. doi:
10.1016/j.jchromb.2015.12.053. [PMID: 26773885] - Michael M Page, Amanda J Hooper, John R Burnett. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?.
Expert opinion on pharmacotherapy.
2016; 17(2):275-81. doi:
10.1517/14656566.2016.1129402. [PMID: 26642232] - Ben J Wu, Sudichhya Shrestha, Kwok L Ong, Douglas Johns, Louise L Dunn, Liming Hou, Philip J Barter, Kerry-Anne Rye. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
International journal of cardiology.
2015 Nov; 199(?):204-12. doi:
10.1016/j.ijcard.2015.07.014. [PMID: 26204569] - Sam J L van der Tuin, Susan Kühnast, Jimmy F P Berbée, Lars Verschuren, Elsbet J Pieterman, Louis M Havekes, José W A van der Hoorn, Patrick C N Rensen, J Wouter Jukema, Hans M G Princen, Ko Willems van Dijk, Yanan Wang. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
Journal of lipid research.
2015 Nov; 56(11):2085-93. doi:
10.1194/jlr.m057794. [PMID: 26342106] - Philip J Barter, Stephen J Nicholls, John J P Kastelein, Kerry-Anne Rye. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
Circulation.
2015 Aug; 132(5):423-32. doi:
10.1161/circulationaha.114.014025. [PMID: 26240263] - G Kees Hovingh, Kausik K Ray, S Matthijs Boekholdt. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?.
Circulation.
2015 Aug; 132(5):433-40. doi:
10.1161/circulationaha.115.014026. [PMID: 26240264] - John J P Kastelein, Joost Besseling, Sukrut Shah, Jean Bergeron, Gisle Langslet, G Kees Hovingh, Naab Al-Saady, Michiel Koeijvoets, John Hunter, Amy O Johnson-Levonas, Jennifer Fable, Aditi Sapre, Yale Mitchel. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet (London, England).
2015 May; 385(9983):2153-61. doi:
10.1016/s0140-6736(14)62115-2. [PMID: 25743173] - Francisco J Rios, Karla B Neves, Aurelie Nguyen Dinh Cat, Sarah Even, Roberto Palacios, Augusto C Montezano, Rhian M Touyz. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
The Journal of pharmacology and experimental therapeutics.
2015 Apr; 353(1):27-34. doi:
10.1124/jpet.114.221002. [PMID: 25617244] - Ben J Wu, Sudichhya Shrestha, Kwok L Ong, Douglas Johns, Liming Hou, Philip J Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
Arteriosclerosis, thrombosis, and vascular biology.
2015 Mar; 35(3):628-36. doi:
10.1161/atvbaha.114.304747. [PMID: 25633313] - Eliot A Brinton, Uma Kher, Sukrut Shah, Christopher P Cannon, Michael Davidson, Antonio M Gotto, Tanya B Ashraf, Christine McCrary Sisk, Hayes Dansky, Yale Mitchel, Philip Barter. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Journal of clinical lipidology.
2015 Jan; 9(1):65-71. doi:
10.1016/j.jacl.2014.10.005. [PMID: 25670362] - Ronald M Krauss, Cathy Anne Pinto, Yang Liu, Amy O Johnson-Levonas, Hayes M Dansky. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Journal of clinical lipidology.
2015 Jan; 9(1):93-102. doi:
10.1016/j.jacl.2014.09.013. [PMID: 25670366] - Eric J Niesor, Evelyne Chaput, Jean-Luc Mary, Andreas Staempfli, Andreas Topp, Andrea Stauffer, Haiyan Wang, Alexandre Durrwell. Effect of compounds affecting ABCA1 expression and CETP activity on the HDL pathway involved in intestinal absorption of lutein and zeaxanthin.
Lipids.
2014 Dec; 49(12):1233-43. doi:
10.1007/s11745-014-3958-8. [PMID: 25300953] - Hiroshi Mabuchi, Atsushi Nohara, Akihiro Inazu. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Molecules and cells.
2014 Nov; 37(11):777-84. doi:
10.14348/molcells.2014.0265. [PMID: 25410905] - Antonio M Gotto, Uma Kher, Manash Shankar Chatterjee, Yang Liu, Xiujiang Susie Li, Sanskruti Vaidya, Christopher P Cannon, Eliot A Brinton, Jennifer E Moon, Sukrut Shah, Hayes M Dansky, Yale Mitchel, Philip Barter. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
Journal of cardiovascular pharmacology and therapeutics.
2014 Nov; 19(6):543-9. doi:
10.1177/1074248414529621. [PMID: 24737712] - Brett Lauring, Xiujiang Susie Li, Yang Liu, Christy Corr, Nicole Lazarus, Josee Cote, Patrick Larson, Amy O Johnson Levonas, Kenneth C Lasseter, Richard A Preston, William B Smith, Eseng Lai, John A Wagner. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
Journal of clinical pharmacology.
2014 Nov; 54(11):1247-55. doi:
10.1002/jcph.320. [PMID: 24782116] - Tarja Äijänen, Artturi Koivuniemi, Matti Javanainen, Sami Rissanen, Tomasz Rog, Ilpo Vattulainen. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
PLoS computational biology.
2014 Nov; 10(11):e1003987. doi:
10.1371/journal.pcbi.1003987. [PMID: 25412509] - François Briand, Quentin Thieblemont, Elodie Muzotte, Noémie Burr, Isabelle Urbain, Thierry Sulpice, Douglas G Johns. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
European journal of pharmacology.
2014 Oct; 740(?):135-43. doi:
10.1016/j.ejphar.2014.06.022. [PMID: 25008069] - Thomas P Roddy, David G McLaren, Ying Chen, Dan Xie, Keiana Dunn, Alison Kulick, Daphne Szeto, Gail Forrest, Kelly Albanese, Marcie Donnelly, Cesaire Gai, Andrew Gewain, Harmony Lederman, Kristian K Jensen, Xi Ai, Petr Vachal, Karen O Akinsanya, Michele A Cleary, Stephen F Previs, Hayes M Dansky, Douglas G Johns. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.
European journal of pharmacology.
2014 Oct; 740(?):410-6. doi:
10.1016/j.ejphar.2014.04.015. [PMID: 24769414] - Lacey B Robinson, William H Frishman. Anacetrapib: a potential new therapy for dyslipidemia.
Cardiology in review.
2014 Sep; 22(5):253-61. doi:
10.1097/crd.0000000000000023. [PMID: 24618931] - Bin Dong, Amar Bahadur Singh, Chin Fung, Kelvin Kan, Jingwen Liu. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Atherosclerosis.
2014 Aug; 235(2):449-62. doi:
10.1016/j.atherosclerosis.2014.05.931. [PMID: 24950000] - Nathan B Mantlo, Ana Escribano. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
Journal of medicinal chemistry.
2014 Jan; 57(1):1-17. doi:
10.1021/jm400574e. [PMID: 23941686] - Antonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, Sanskruti Vaidya, Uma Kher, Eliot A Brinton, Michael Davidson, Jennifer E Moon, Sukrut Shah, Hayes M Dansky, Yale Mitchel, Philip Barter. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
The American journal of cardiology.
2014 Jan; 113(1):76-83. doi:
10.1016/j.amjcard.2013.08.041. [PMID: 24188894] - Daniel J Rader, Emil M deGoma. Future of cholesteryl ester transfer protein inhibitors.
Annual review of medicine.
2014; 65(?):385-403. doi:
10.1146/annurev-med-050311-163305. [PMID: 24422575] - Hyun Joon Shin, Peter A McCullough. Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Nephron. Clinical practice.
2014; 127(1-4):158-64. doi:
10.1159/000363552. [PMID: 25343842] - Ioanna Gouni-Berthold, Heiner K Berthold. Familial hypercholesterolemia: etiology, diagnosis and new treatment options.
Current pharmaceutical design.
2014; 20(40):6220-9. doi:
10.2174/1381612820666140620125213. [PMID: 24953396] - Michael B Boffa, Marlys L Koschinsky. Screening for and management of elevated Lp(a).
Current cardiology reports.
2013 Nov; 15(11):417. doi:
10.1007/s11886-013-0417-8. [PMID: 24057771] - Thomas A Bell, Mark J Graham, Richard G Lee, Adam E Mullick, Wuxia Fu, Dan Norris, Rosanne M Crooke. Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.
Journal of lipid research.
2013 Oct; 54(10):2647-57. doi:
10.1194/jlr.m036509. [PMID: 23801661] - Sheng-Ping Wang, Erin Daniels, Ying Chen, Jose Castro-Perez, Haihong Zhou, Karen O Akinsanya, Stephen F Previs, Thomas P Roddy, Douglas G Johns. In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.
Journal of lipid research.
2013 Oct; 54(10):2858-65. doi:
10.1194/jlr.m041541. [PMID: 23898048] - Amir Hooshang Mohammadpour, Fatemeh Akhlaghi. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Clinical pharmacokinetics.
2013 Aug; 52(8):615-26. doi:
10.1007/s40262-013-0071-8. [PMID: 23658137] - M Ezzahti, E J G Sijbrands, M T Mulder, J E Roeters van Lennep. Familial hypercholesterolaemia: new treatment options.
The Netherlands journal of medicine.
2013 Jun; 71(5):227-33. doi:
". [PMID: 23799308] - Seongah Han, Lauretta Levoci, Paul Fischer, Sheng-Ping Wang, Karen Gagen, Ying Chen, Dan Xie, Timothy Fisher, Anka G Ehrhardt, Andrea M Peier, Douglas G Johns. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.
Biochimica et biophysica acta.
2013 Apr; 1831(4):825-33. doi:
10.1016/j.bbalip.2012.12.008. [PMID: 23269286] - Michael Davidson, Sherry Xueyu Liu, Philip Barter, Eliot A Brinton, Christopher P Cannon, Antonio M Gotto, Elizabeth T Leary, Sukrut Shah, Michael Stepanavage, Yale Mitchel, Hayes M Dansky. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Journal of lipid research.
2013 Feb; 54(2):467-72. doi:
10.1194/jlr.m032615. [PMID: 23172660] - Chuanwei Li, Wen Zhang, Faying Zhou, Caiyu Chen, Liang Zhou, Yafei Li, Ling Liu, Fang Pei, Hao Luo, Zhangxue Hu, Jing Cai, Chunyu Zeng. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
PloS one.
2013; 8(10):e77049. doi:
10.1371/journal.pone.0077049. [PMID: 24204732] - Mariarita Puntoni, Francesco Sbrana, Federico Bigazzi, Tiziana Sampietro. Tangier disease: epidemiology, pathophysiology, and management.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2012 Oct; 12(5):303-11. doi:
10.2165/11634140-000000000-00000. [PMID: 22913675] - Philip J Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
Journal of lipid research.
2012 Sep; 53(9):1755-66. doi:
10.1194/jlr.r024075. [PMID: 22550134] - Michael H Davidson. HDL and CETP Inhibition: Will This DEFINE the Future?.
Current treatment options in cardiovascular medicine.
2012 Aug; 14(4):384-90. doi:
10.1007/s11936-012-0191-8. [PMID: 22723175] - Bernd Hewing, Edward A Fisher. Rationale for cholesteryl ester transfer protein inhibition.
Current opinion in lipidology.
2012 Aug; 23(4):372-6. doi:
10.1097/mol.0b013e328353ef1d. [PMID: 22517614] - Maria-Carmen Fernandez, Ana Escribano, Ana I Mateo, Saravanan Parthasarathy, Eva M Martin de la Nava, Xiaodong Wang, Sandra L Cockerham, Thomas P Beyer, Robert J Schmidt, Guoqing Cao, Youyan Zhang, Timothy M Jones, Anthony Borel, Stephanie A Sweetana, Ellen A Cannady, Gregory Stephenson, Scott Frank, Nathan B Mantlo. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Bioorganic & medicinal chemistry letters.
2012 May; 22(9):3056-62. doi:
10.1016/j.bmcl.2012.03.075. [PMID: 22497761] - Wijtske Annema, Uwe Jf Tietge. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.
Nutrition & metabolism.
2012 Mar; 9(1):25. doi:
10.1186/1743-7075-9-25. [PMID: 22458435] - Douglas G Johns, Joseph Duffy, Timothy Fisher, Brian K Hubbard, Michael J Forrest. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Drugs.
2012 Mar; 72(4):491-507. doi:
10.2165/11599310-000000000-00000. [PMID: 22356288] - Ronald M Krauss, Kathleen Wojnooski, Joseph Orr, J Casey Geaney, Cathy Anne Pinto, Yang Liu, John A Wagner, Julie Mabalot Luk, Amy O Johnson-Levonas, Matt S Anderson, Hayes M Dansky. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.
Journal of lipid research.
2012 Mar; 53(3):540-547. doi:
10.1194/jlr.m018010. [PMID: 22180633] - Hisashi Shinkai. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Vascular health and risk management.
2012; 8(?):323-31. doi:
10.2147/vhrm.s25238. [PMID: 22661899] - Artturi Koivuniemi, Timo Vuorela, Petri T Kovanen, Ilpo Vattulainen, Marja T Hyvönen. Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations.
PLoS computational biology.
2012 Jan; 8(1):e1002299. doi:
10.1371/journal.pcbi.1002299. [PMID: 22253581] - Alyse S Goldberg, Robert A Hegele. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Drug design, development and therapy.
2012; 6(?):251-9. doi:
10.2147/dddt.s34976. [PMID: 23055695] - D E Gutstein, R Krishna, D Johns, H K Surks, H M Dansky, S Shah, Y B Mitchel, J Arena, J A Wagner. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
Clinical pharmacology and therapeutics.
2012 Jan; 91(1):109-22. doi:
10.1038/clpt.2011.271. [PMID: 22130116] - Klaus G Parhofer. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Core evidence.
2012; 7(?):29-38. doi:
10.2147/ce.s25239. [PMID: 22701100] - Gregor Dernick, Stefan Obermüller, Cyrill Mangold, Christine Magg, Hugues Matile, Oliver Gutmann, Elisabeth von der Mark, Corinne Handschin, Cyrille Maugeais, Eric J Niesor. Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.
Journal of lipid research.
2011 Dec; 52(12):2323-2331. doi:
10.1194/jlr.d016824. [PMID: 21971713] - B Sjouke, D M Kusters, J J P Kastelein, G K Hovingh. Familial hypercholesterolemia: present and future management.
Current cardiology reports.
2011 Dec; 13(6):527-36. doi:
10.1007/s11886-011-0219-9. [PMID: 21938413] - Philip Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?.
Trends in pharmacological sciences.
2011 Dec; 32(12):694-9. doi:
10.1016/j.tips.2011.07.004. [PMID: 22088767] - Paul J W H Kappelle, Arie van Tol, Bruce H R Wolffenbuttel, Robin P F Dullaart. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Cardiovascular therapeutics.
2011 Dec; 29(6):e89-99. doi:
10.1111/j.1755-5922.2010.00201.x. [PMID: 20645987] - Jose Castro-Perez, François Briand, Karen Gagen, Sheng-Ping Wang, Ying Chen, David G McLaren, Vinit Shah, Rob J Vreeken, Thomas Hankemeier, Thierry Sulpice, Thomas P Roddy, Brian K Hubbard, Douglas G Johns. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
Journal of lipid research.
2011 Nov; 52(11):1965-73. doi:
10.1194/jlr.m016410. [PMID: 21841206] - Cesare R Sirtori. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Expert opinion on investigational drugs.
2011 Nov; 20(11):1543-54. doi:
10.1517/13543784.2011.614946. [PMID: 21961529] - Kristina Duwensee, Stefan Schwaiger, Ivan Tancevski, Kathrin Eller, Miranda van Eck, Patrick Markt, Tobias Linder, Ursula Stanzl, Andreas Ritsch, Josef R Patsch, Daniela Schuster, Hermann Stuppner, David Bernhard, Philipp Eller. Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein.
Atherosclerosis.
2011 Nov; 219(1):109-15. doi:
10.1016/j.atherosclerosis.2011.07.023. [PMID: 21820657] - Santiago Redondo, José Martínez-González, Concha Urraca, Teresa Tejerina. Emerging therapeutic strategies to enhance HDL function.
Lipids in health and disease.
2011 Oct; 10(?):175. doi:
10.1186/1476-511x-10-175. [PMID: 21985435] - Hayes M Dansky, Daniel Bloomfield, Patrice Gibbons, Sherry Liu, Christine McCrary Sisk, Diane Tribble, James M McKenney, Thomas W Littlejohn, Yale Mitchel. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
American heart journal.
2011 Oct; 162(4):708-16. doi:
10.1016/j.ahj.2011.07.010. [PMID: 21982664] - Mohammed F Abdul-Mohsen. Medical angioplasty - hope and expectations: an optimistic overview.
Journal of family & community medicine.
2011 Sep; 18(3):101-10. doi:
10.4103/2230-8229.90007. [PMID: 22175036]